 CAMBRIDGE, Mass., April 28, 2021 PRNewswire -- Akebia Therapeutics, Inc. Nasdaq: AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the New England Journal of Medicine NEJM has published the results of the global Phase 3 clinical program of vadadustat for the treatment of anemia due to chronic kidney disease CKD in adult patients on dialysis INNO2VATE and adult patients not on dialysis PRO2TECT in two separate manuscripts. 